Cargando…

Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients

BACKGROUND: We have previously shown that glycine increases fat‐free mass in chronic haemodialysis patients with features of malnutrition as compared with branched‐chain amino acids (BCAAs). This multicentre randomized double‐blind crossover study evaluates the impact of these amino acids on the gut...

Descripción completa

Detalles Bibliográficos
Autores principales: Genton, Laurence, Pruijm, Menno, Teta, Daniel, Bassi, Isabelle, Cani, Patrice D., Gaïa, Nadia, Herrmann, François R., Marangon, Nicola, Mareschal, Julie, Muccioli, Giulio G., Stoermann, Catherine, Suriano, Francesco, Wurzner‐Ghajarzadeh, Arlene, Lazarevic, Vladimir, Schrenzel, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718035/
https://www.ncbi.nlm.nih.gov/pubmed/34535959
http://dx.doi.org/10.1002/jcsm.12781
_version_ 1784624635667546112
author Genton, Laurence
Pruijm, Menno
Teta, Daniel
Bassi, Isabelle
Cani, Patrice D.
Gaïa, Nadia
Herrmann, François R.
Marangon, Nicola
Mareschal, Julie
Muccioli, Giulio G.
Stoermann, Catherine
Suriano, Francesco
Wurzner‐Ghajarzadeh, Arlene
Lazarevic, Vladimir
Schrenzel, Jacques
author_facet Genton, Laurence
Pruijm, Menno
Teta, Daniel
Bassi, Isabelle
Cani, Patrice D.
Gaïa, Nadia
Herrmann, François R.
Marangon, Nicola
Mareschal, Julie
Muccioli, Giulio G.
Stoermann, Catherine
Suriano, Francesco
Wurzner‐Ghajarzadeh, Arlene
Lazarevic, Vladimir
Schrenzel, Jacques
author_sort Genton, Laurence
collection PubMed
description BACKGROUND: We have previously shown that glycine increases fat‐free mass in chronic haemodialysis patients with features of malnutrition as compared with branched‐chain amino acids (BCAAs). This multicentre randomized double‐blind crossover study evaluates the impact of these amino acids on the gut barrier and microbiota. METHODS: Haemodialysis patients were included if they had plasma albumin <38 g/L or weight loss >5% of dry body weight, and daily dietary intakes <30 kcal/kg and <1 g protein/kg. They consumed glycine or BCAA (7 g twice daily) for 4 months and underwent a 1 month washout period, before crossover of supplementations. Faecal microbiota (16S rRNA gene sequencing) and immunoglobulin A (IgA), serum levels of cytokines, surrogate markers of intestinal permeability, appetite mediators, and endocannabinoids were obtained at the start and end of each supplementation. Supplementations were compared by multiple mixed linear regression models, adjusted for age, sex, month of supplementation (0 and 4 in each period), and period (Period 1: first 4 months; Period 2: last 4 months). Microbiota comparisons were performed using principal coordinate analysis and permutational multivariate analysis of variance, Shannon diversity index estimate and analysis of composition of microbiomes analysis, and Wilcoxon tests. RESULTS: We analysed 27 patients compliant to the supplementations. Multiple mixed linear regression models were significant only for interleukin‐6 (P = 0.002), glucagon‐like peptide 1 (P = 0.028), cholecystokinin (P = 0.021), and peptide YY (P = 0.002), but not for the other outcomes. The significant models did not show any impact of the type of supplementation (P < 0.05 in all models). Principal coordinate analysis and permutational multivariate analysis of variance (P = 0.0001) showed strong microbiota clustering by subject, but no effect of the amino acids. Bacterial alpha diversity and zero‐radius operational taxonomic unit richness remained stable, whatever the supplementation. Lacticaseibacillus paracasei (0.030; Q1–Q3 0.008–0.078 vs. 0.004; Q1–Q3 0.001–0.070) and Bifidobacterium dentium (0.0247; Q1–Q3 0.002–0.191 vs. 0.003; Q1–Q3 0.001–0.086) significantly decreased with the BCAA supplementation. CONCLUSIONS: The BCAA and glycine supplementations had no impact on the serum levels of cytokines, appetite mediators, intestinal permeability, endocannabinoids, or faecal IgA. Overall faecal microbiota composition and microbial diversity did not change with the glycine or BCAA supplementation but decreased the abundance of L. paracasei and B. dentium.
format Online
Article
Text
id pubmed-8718035
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87180352022-01-06 Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients Genton, Laurence Pruijm, Menno Teta, Daniel Bassi, Isabelle Cani, Patrice D. Gaïa, Nadia Herrmann, François R. Marangon, Nicola Mareschal, Julie Muccioli, Giulio G. Stoermann, Catherine Suriano, Francesco Wurzner‐Ghajarzadeh, Arlene Lazarevic, Vladimir Schrenzel, Jacques J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: We have previously shown that glycine increases fat‐free mass in chronic haemodialysis patients with features of malnutrition as compared with branched‐chain amino acids (BCAAs). This multicentre randomized double‐blind crossover study evaluates the impact of these amino acids on the gut barrier and microbiota. METHODS: Haemodialysis patients were included if they had plasma albumin <38 g/L or weight loss >5% of dry body weight, and daily dietary intakes <30 kcal/kg and <1 g protein/kg. They consumed glycine or BCAA (7 g twice daily) for 4 months and underwent a 1 month washout period, before crossover of supplementations. Faecal microbiota (16S rRNA gene sequencing) and immunoglobulin A (IgA), serum levels of cytokines, surrogate markers of intestinal permeability, appetite mediators, and endocannabinoids were obtained at the start and end of each supplementation. Supplementations were compared by multiple mixed linear regression models, adjusted for age, sex, month of supplementation (0 and 4 in each period), and period (Period 1: first 4 months; Period 2: last 4 months). Microbiota comparisons were performed using principal coordinate analysis and permutational multivariate analysis of variance, Shannon diversity index estimate and analysis of composition of microbiomes analysis, and Wilcoxon tests. RESULTS: We analysed 27 patients compliant to the supplementations. Multiple mixed linear regression models were significant only for interleukin‐6 (P = 0.002), glucagon‐like peptide 1 (P = 0.028), cholecystokinin (P = 0.021), and peptide YY (P = 0.002), but not for the other outcomes. The significant models did not show any impact of the type of supplementation (P < 0.05 in all models). Principal coordinate analysis and permutational multivariate analysis of variance (P = 0.0001) showed strong microbiota clustering by subject, but no effect of the amino acids. Bacterial alpha diversity and zero‐radius operational taxonomic unit richness remained stable, whatever the supplementation. Lacticaseibacillus paracasei (0.030; Q1–Q3 0.008–0.078 vs. 0.004; Q1–Q3 0.001–0.070) and Bifidobacterium dentium (0.0247; Q1–Q3 0.002–0.191 vs. 0.003; Q1–Q3 0.001–0.086) significantly decreased with the BCAA supplementation. CONCLUSIONS: The BCAA and glycine supplementations had no impact on the serum levels of cytokines, appetite mediators, intestinal permeability, endocannabinoids, or faecal IgA. Overall faecal microbiota composition and microbial diversity did not change with the glycine or BCAA supplementation but decreased the abundance of L. paracasei and B. dentium. John Wiley and Sons Inc. 2021-09-18 2021-12 /pmc/articles/PMC8718035/ /pubmed/34535959 http://dx.doi.org/10.1002/jcsm.12781 Text en © 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Genton, Laurence
Pruijm, Menno
Teta, Daniel
Bassi, Isabelle
Cani, Patrice D.
Gaïa, Nadia
Herrmann, François R.
Marangon, Nicola
Mareschal, Julie
Muccioli, Giulio G.
Stoermann, Catherine
Suriano, Francesco
Wurzner‐Ghajarzadeh, Arlene
Lazarevic, Vladimir
Schrenzel, Jacques
Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients
title Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients
title_full Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients
title_fullStr Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients
title_full_unstemmed Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients
title_short Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients
title_sort gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718035/
https://www.ncbi.nlm.nih.gov/pubmed/34535959
http://dx.doi.org/10.1002/jcsm.12781
work_keys_str_mv AT gentonlaurence gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT pruijmmenno gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT tetadaniel gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT bassiisabelle gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT canipatriced gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT gaianadia gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT herrmannfrancoisr gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT marangonnicola gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT mareschaljulie gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT muccioligiuliog gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT stoermanncatherine gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT surianofrancesco gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT wurznerghajarzadeharlene gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT lazarevicvladimir gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients
AT schrenzeljacques gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients